Robert R. Ruffolo Jr.
Robert R. Ruffolo (born April, 1950, in Yonkers, N.Y.) was president of research and development for Wyeth Pharmaceuticals, and corporate Senior Vice President of Wyeth from 2001 to 2008.[1][2] During his career in the pharmaceutical industry, Ruffolo played a significant role in the discovery and/or development of a number of marketed products, including dobutamine (Dobutrex) for the acute management of congestive heart failure, and eprosartan (Teveten) for hypertension.
Biography
Robert R. Ruffolo, Jr. was born in April 1950, in Yonkers, N.Y.
He had Bachelor of Science in pharmacy, 1973, Ohio State University; PhD in pharmacology, 1976, also in Ohio.
Spent a few years as a fellow at the National Institutes of Health, then spent 6 years at Eli Lilly & Co. and 17 years at SmithKline Beecham in various research positions. He joined Wyeth in 2000.
Ruffolo has authored nearly 500 full-length publications and 200 abstracts, and has edited 17 books. He is currently the Editor-in-Chief of Current Opinions in Pharmacology. Ruffolo has served on the editorial boards of 28 international scientific journals. The American Society for Information Science and Technology designated Ruffolo as a Highly Cited Scientist for being among the top one-hundred most cited pharmacologists in the world over the past two decades.
Robert is married and has three children.
Awards
Ruffolo received a number of prestigious awards, including
- Chief Scientific Officer of the Year (2004),
- George B. Koelle Award for Scientific Excellence (2005),
- Lorenzini Gold Medal for Biomedical Research (1999),
- John Jacob Abel Award in Pharmacology (1988),
- Prix Galien Special Commendation for Excellence and Innovation in Research (1996),
- the Distinguished Alumni Award from The Ohio State University (1989).
On 30 November 2007, Ruffolo received a Degree Honoris Causa in Management Engineering from the University of Catania in Sicily, Italy.
References
- ^ GINA KOLATA (March 28, 2004). "Ideas & Trends: Of Mice and Men; Why Test Animals to Cure Human Depression?". The New York Times. Retrieved 2010-12-26.
But Dr. Robert R. Ruffolo, president of research and development at Wyeth, said it was a mistake to assume that an animal test can reflect human behavior. '
{{cite news}}: Italic or bold markup not allowed in:|publisher=(help) - ^ ANDREW POLLACK (June 14, 2010). "Awaiting the Genome Payoff". The New York Times. Retrieved 2010-12-26.
"If on the first day we had discovered a new molecular target, it's still going to take 15 to 20 years to make the drug," said Robert R. Ruffolo Jr., who ran research and development at Wyeth until 2008.
{{cite news}}: Italic or bold markup not allowed in:|publisher=(help)